COMPLEMENTARY AND ALTERNATIVE THERAPIES
Time: 7:00 – 7:40 pm ET | Meeting Password: 3Mh55F
Carin S. Waslo,1,2 M. Mateo Paz Soldan,3,4 Mark S. Freedman,5 Pavle Repovic,6 Andrew J. Solomon,7 John R. Rinker,8 Mitchell T. Wallin,9 Jodie K. Haselkorn,10 Rebecca I. Spain11
1Neurology, VA Portland Health Care System, Portland, OR; 2Neurology, Oregon Health & Science University, Portland, OR; 3Neurology, University of Utah, Salt Lake City, UT;Â 4Neurology, VA Salt Lake City HCS, Salt Lake City, UT; 5University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada; 6Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA; 7Neurological Sciences, University of Vermont College of Medicine, Burlington, VT; 8Neurology, University of Alabama at Birmingham,
Birmingham, AL; 9Washington, DC VAMC, MS Center of Excellence, Washington, DC;Â 10Department of Epidemiology, University of Washington, Seattle, WA; 11Oregon Health & Science University, Portland, OR
CASE REPORT AND CASE SERIES
Allison N. Block, Ahmed Z. Obeidat
Neurology, Medical College of Wisconsin, Milwaukee, WI
Time: 7:30 – 8:10 pm ET
Astrid Diaz, Viviana Martinez, Ivonne Vicente, Cristina M. Rubi, Angel Lopez, Angel Chinea
San Juan Multiple Sclerosis Center, Guaynabo, PR
Time: 7:00 – 7:40 pm ET | Meeting Password: 3Wgty4
Time: 7:00 – 7:40 pm ET
Time: 7:30 – 8:10 pm ET | Meeting Password: 6Au0i6
Meeting Password: 0VuS52
Time: 7:45 pm – 8:30 pm ET | Meeting Password: SGpVdDlHQVEwNEFJT2FMeDl2OFVzUT09
Time: 7:00 pm – 7:40 pm ET | Meeting Password: 298147
DISEASE MODIFYING THERAPIES PART 1
Amber Salter,1 Samantha Lancia,1 Gary Cutter,2 Robert J. Fox,3 Ruth Ann Marrie,4 Jason P. Mendoza,5 James B. Lewin5
1Biostatistics, Washington University School in St. Louis, School of Medicine, St. Louis, MO; 2Biostatistics, University of Alabama at Birmingham, Birmingham, AL; 3Cleveland Clinic, Cleveland, OH; 4Health Sciences Centre Winnipeg, University of Manitoba, Winnipeg, MB, Canada; 5Biogen, Cambridge, MA
Amit Bar-Or,1 Stanley L. Cohan,2 Patricia K. Coyle,3 Fred D. Lublin,4 Xiangyi Meng,5 Wendy Su,5 Bruce A.C. Cree,6
1Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 2Providence Multiple Sclerosis Center, Providence Brain Institute, Portland, OR; 3Stony Brook University, Stony Brook, NY; 4Icahn School of Medicine at Mount Sinai, New York, NY; 5Novartis Pharmaceuticals Corporation, East Hanover, NJ; 6Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA
Amit Bar-Or,1 Bruce A.C. Cree,2 Le H. Hua,3 Amos Katz,4 Derrick Robertson,5 Brandon Brown,6 Desiree Dunlop,6 Xiangyi Meng,6 Wendy Su6
1Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 2Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA; 3Lou Ruvo Center for Brain Health, Las Vegas, NV; 4Linda Cardinale MS Center, Freehold, NJ; 5University of South Florida, Multiple Sclerosis Center, Tampa, FL; 6Novartis Pharmaceuticals Corporation, East Hanover, NJ
Annette Wundes,1 Enrique Alvarez,2 Mark S. Freedman,3 Oksana Mokliatchouk,4 Hailu Chen,4 Shivani Kapadia,4 Jordan Messer,4 Robert T. Naismith5
1Department of Neurology, University of Washington Medical Center, Seattle, WA; 2Department of Neurology, University of Colorado School of Medicine, Aurora, CO; 3University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada; 4Biogen, Cambridge, MA; 5Washington University School of Medicine, St. Louis, MO
Barry Singer,1 Gavin Giovannoni,2 Nicola De Stefano,3 Matt Mandel,4 Yann Hyvert,5 Julie Aldridge,4 Andrew Galazka,6 Caroline Lemieux,7 Mark S. Freedman8
1Missouri Baptist Medical Center, St Louis, MO; 2Blizard Institute of Cell and Molecular Science, London, United Kingdom; 3University of Siena, Siena, Italy; 4EMD Serono Inc, Billerica, MA; 5Merck KGaA, Darmstadt, Germany; 6Merck, Aubonne, Switzerland; 7EMD Serono Inc., Mississauga, ON, Canada; 8University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada
Bruce A.C. Cree,1 Robert J. Fox,2 Gavin Giovannoni,3 Patrick Vermersch,4 Amit Bar-Or,5 Ralf Gold,6 Nicolas Rouyrre,7 Goeril Karlsson,7 Frank Dahlke,7 Ludwig Kappos8
1Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA; 2Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH; 3Queen Mary University of London, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, United Kingdom; 4Department of Neurology, University of Lille, CHU Lille, Lille, France; 5Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 6Department of Neurology, St. Josef-Hospital/Ruhr-University Bochum, Bochum, Germany; 7Novartis Pharma AG, Basel, Switzerland; 8Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Basel, Switzerland
Carrie M. Hersh,1 Richard A. Brook,2 Ian A. Beren,3 Nicholas J. Rohrbacker,3 Lori Lebson,4 Christian Henke,5 Amy L. Phillips6
1Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV; 2Better Health Worldwide, Inc, Newfoundland, NJ; 3The HCMS Group, LLC, Pittsburgh, PA; 4EMD Serono, Inc, Rockland, MA; 5Merck KGaA, Darmstadt, Germany; 6Health Economics & Outcomes Research, EMD Serono, Inc, Rockland, MA
Irina Kalatskaya,1 Gavin Giovannoni,2,3 Thomas P. Leist,4 Per Soelberg-Sorensen,5 Ursula Boschert,6 Julie DeMartino,1 Alex Rolfe1
1EMD Serono, Inc, Billerica, MA; 2Blizard Institute of Cell and Molecular Science, London, United Kingdom; 3Queen Mary University of London, London, United Kingdom; 4Jefferson University Hospital, Philadelphia, PA; 5Department of Neurology, Danish MS Center, University of Copenhagen, Copenhagen, Denmark; 6Merck Serono S.A., Eysins, Switzerland